Why Nevolat® ?
Nevolat® is a generic version of Saxenda® (liraglutide) and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults and adolescents with a specific Body Mass Index (BMI). Please refer to therapeutic indications or the SmPC.1,2
It suppresses appetite and increases satiety, reducing bodyweight and improves glycaemic control (particularly in pre-diabetic and diabetic patients) helping your patients to make a daily difference in their long-term sustainable weight management journey.1
Nevolat® is a generic version of Saxenda® (liraglutide) and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults and adolescents with a specific Body Mass Index (BMI). Please refer to therapeutic indications or the SmPC.1,2
It suppresses appetite and increases satiety, reducing bodyweight and improves glycaemic control (particularly in pre-diabetic and diabetic patients) helping your patients to make a daily difference in their long-term sustainable weight management journey.1
APPETITE SUPPRESSION & SATIETY INCREASE
Nevolat® targets native GLP-1 receptors to amplify glucose-dependent insulin secretion from the pancreatic beta cells and acts as a physiological regulator of appetite and food intake.1
For more info see Mechanism of Action and Pharmacodynamics.
BIOEQUIVALENCE
Nevolat® offers bioequivalence to Saxenda® (liraglutide) and met the bioequivalence criteria in terms of rate and extent of absorption after administration of a single dose (both pre-filled pens) under fasting conditions.2
SUSTAINABLE WEIGHT LOSS
In the SCALE maintenance trial the percentage of patients who maintained weight loss achieved prior to treatment initiation was 81.4% with liraglutide compared to 48.9% with placebo. (Over a 56-week trial, estimated odds ratio 4.8 (3.0; 7.7), P<0.0001).2,3
DAILY DOSING
Daily dosing helps keep patients focused on their weight management objectives every day.
BMI, Body Mass Index; GLP-1 RA, glucagon-like peptide-1 receptor agonist; SmPC, Summary of Product Characteristics.
- Nevolat® (liraglutide) Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/100226/smpc. Accessed on December 2024.
- Liraglutide bioequivalence. Data on File. Zentiva, August 2024.
- Wadden TA, Hollander P, Klein S, et al. Weight Maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Intl J Obes (2013) 37(11):1443–1
000697581 | December 2024